☆ 4.6 Article

In vitro and Intracellular Antibacterial Activity of Sudapyridine (WX-081) Against Tuberculosis

INFECTION AND DRUG RESISTANCE (2023)

Related references

Note: Only part of the references are listed.

Article Microbiology

Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis

Rong Yao et al.

Microbiology Spectrum (2022)

Add to Collection

Article Microbiology

Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naive TB patients in Pakistan

Dania Khalid Saeed et al.

Summary: Mutations in genes such as Rv0678 are commonly associated with bedaquiline resistance in Mycobacterium tuberculosis, while variants in efflux pump genes were also found to be present in drug resistant isolates, indicating their potential role in resistance mechanisms.

BMC MICROBIOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent

Zhigang Huang et al.

Summary: Bedaquiline is a drug used for the treatment of multidrug-resistant tuberculosis, but its side effects limit its clinical use. Based on bedaquiline, a new drug called WX-081 has been developed with better efficacy and safety. Currently, WX-081 is undergoing phase II clinical trials.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)

Add to Collection

Article Immunology

Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019

Yousra Kherabi et al.

Summary: Resistance to fluoroquinolones and additional resistance to bedaquiline or linezolid in MDR TB, known as pre-XDR TB and XDR TB, have implications for treatment outcomes and safety. Pre-XDR/XDR TB was associated with certain clinical characteristics and longer treatment duration, but did not significantly affect treatment outcomes or increase the risk of serious adverse events compared with fluoroquinolone-susceptible MDR TB.

EMERGING INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Loss of Smell and Taste Among Healthcare Personnel Screened for Coronavirus 2019

Russell R. Kempker et al.

Summary: Among 283 symptomatic healthcare personnel tested for SARS-CoV-2, 18% tested positive. Among the 51 positive cases, self-reported loss of smell and taste were common symptoms, with high specificity for a positive SARS-CoV-2 test.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article

Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients

Denny Ardhianto et al.

Journal of Basic and Clinical Physiology and Pharmacology (2021)

Add to Collection

Article Microbiology

Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan

Sheng-Han Wu et al.

Summary: This study found that redefining the intermediate susceptibility category for BDQ resistance and conducting genotypic analyses for MGIT-BDQ borderline resistance isolates are recommended to better manage drug-resistant tuberculosis cases. Additionally, the study observed that Rv0678 mutations were not a robust marker of BDQ resistance and were not associated with treatment outcomes in BDQ-resistant patients without exposure.

FRONTIERS IN MICROBIOLOGY (2021)

Add to Collection

Article Microbiology

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Precious Ngwalero et al.

Summary: The study used LC-MS/MS to measure intracellular concentrations of bedaquiline and its metabolite M2 in RR-TB patients in South Africa, finding that M2 accumulated at significantly higher concentrations intracellularly than bedaquiline. The intracellular-plasma accumulation ratio for bedaquiline and M2 is expected to reach maximum effect after 2 months of treatment.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Pre-extensively drug-resistant tuberculosis spondylodiscitis in an immunocompetent patient: a case report

Safaa Fellous et al.

PAN AFRICAN MEDICAL JOURNAL (2020)

Add to Collection

Article Infectious Diseases

Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis

S. Perrineau et al.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2019)

Add to Collection

Review Immunology

A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity

Harun Patel et al.

TUBERCULOSIS (2019)

Add to Collection

Article Chemistry, Medicinal

Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging

Yang Li et al.

DRUG DEVELOPMENT RESEARCH (2019)

Add to Collection

Review Respiratory System

Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment

Christoph Lange et al.

RESPIROLOGY (2018)

Add to Collection

Article Infectious Diseases

Management of complex tuberculosis cases: a focus on drug-resistant tuberculous meningitis

Ravindra Kumar Garg et al.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)

Add to Collection

Review Immunology

Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention

Thi Van Anh Nguyen et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Microbiology

In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China

Yu Pang et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

Add to Collection

Article Multidisciplinary Sciences

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

K Andries et al.

SCIENCE (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.